Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia
- PMID: 11479730
- DOI: 10.1007/s004390100529
Population-based risk estimates of Wilms tumor in sporadic aniridia. A comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia
Abstract
Aniridia is a severe eye disease characterized by iris hypoplasia; both sporadic cases and familial cases with an autosomal dominant inheritance exist. Mutations in the PAX6 gene have been shown to be the genetic cause of the disease. Some of the sporadic cases are caused by large chromosomal deletions, some of which also include the Wilms tumor gene (WAGR syndrome), resulting in an increased risk of developing Wilms tumor. Based on the unique registration of both cancer and aniridia cases in Denmark, we have made the most accurate risk estimate to date for Wilms tumor in sporadic aniridia. We have found that patients with sporadic aniridia have a relative risk of 67 (confidence interval: 8.1-241) of developing Wilms tumor. Among patients investigated for mutations, Wilms tumor developed in only two patients out of 5 with the Wilms tumor gene (WT1) deleted. None of the patients with smaller chromosomal deletions or intragenic mutations were found to develop Wilms tumor. Our observations suggest a smaller risk for Wilms tumor than previous estimates, and that tumor development requires deletion of WT1. We report a strategy for the mutational analysis of aniridia cases resulting in the detection of mutations in 68% of sporadic cases and 89% of familial cases. We also report four novel mutations in PAX6, and furthermore, we have discovered a new alternatively spliced form of PAX6.
Similar articles
-
Polymerase chain reaction-based risk assessment for Wilms tumor in sporadic aniridia.Am J Ophthalmol. 1998 May;125(5):687-92. doi: 10.1016/s0002-9394(98)00015-4. Am J Ophthalmol. 1998. PMID: 9625553
-
Raised risk of Wilms tumour in patients with aniridia and submicroscopic WT1 deletion.J Med Genet. 2007 Dec;44(12):787-90. doi: 10.1136/jmg.2007.051318. Epub 2007 Jul 14. J Med Genet. 2007. PMID: 17630404 Free PMC article.
-
[Molecular genetic study of the PAX6 gene in aniridia patients].Ophthalmologe. 1998 Dec;95(12):828-30. doi: 10.1007/s003470050361. Ophthalmologe. 1998. PMID: 10025146 German.
-
Aniridia.Eur J Hum Genet. 2012 Oct;20(10):1011-7. doi: 10.1038/ejhg.2012.100. Epub 2012 Jun 13. Eur J Hum Genet. 2012. PMID: 22692063 Free PMC article. Review.
-
Aniridia: recent achievements in paediatric practice.Eur J Pediatr. 1995 Oct;154(10):795-800. doi: 10.1007/BF01959784. Eur J Pediatr. 1995. PMID: 8529675 Review.
Cited by
-
Expanding the Phenotypic Spectrum of PAX6 Mutations: From Congenital Cataracts to Nystagmus.Genes (Basel). 2021 May 9;12(5):707. doi: 10.3390/genes12050707. Genes (Basel). 2021. PMID: 34065151 Free PMC article.
-
Identification of a novel PAX6 mutation in a Chinese family with aniridia.BMC Ophthalmol. 2019 Jan 8;19(1):10. doi: 10.1186/s12886-018-1009-6. BMC Ophthalmol. 2019. PMID: 30621664 Free PMC article.
-
PAX6 Genotypic and Retinal Phenotypic Characterization in Congenital Aniridia.Invest Ophthalmol Vis Sci. 2020 May 11;61(5):14. doi: 10.1167/iovs.61.5.14. Invest Ophthalmol Vis Sci. 2020. PMID: 32396632 Free PMC article.
-
A novel PAX6 variant as the cause of aniridia in a Chinese patient with SRRRD.BMC Med Genomics. 2023 Aug 4;16(1):182. doi: 10.1186/s12920-023-01620-w. BMC Med Genomics. 2023. PMID: 37542296 Free PMC article.
-
The genetic architecture of aniridia and Gillespie syndrome.Hum Genet. 2019 Sep;138(8-9):881-898. doi: 10.1007/s00439-018-1934-8. Epub 2018 Sep 22. Hum Genet. 2019. PMID: 30242502 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases